Yukie Tashiro
Overview
Explore the profile of Yukie Tashiro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
245
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Utsunomiya A, Yasunaga J, Tabuchi T, Nakano N, Odawara J, Kubota A, et al.
Int J Hematol
. 2024 Dec;
121(3):416-420.
PMID: 39719504
Here, we report a rare case of relapsed adult T-cell leukemia-lymphoma (ATL) with evidence of clonal relapse 26 years after initial diagnosis. The patient had been diagnosed with an aggressive...
2.
Sakamoto Y, Ishida T, Masaki A, Murase T, Ohtsuka E, Takeshita M, et al.
Int J Hematol
. 2024 Nov;
121(2):206-221.
PMID: 39586983
Here, we investigated the clinical significance of NOTCH1 and FBXW7 alterations for adult T-cell leukemia/lymphoma (ATLL) treatment outcomes. NOTCH1 alterations were identified in 37 (14.4%) of 257 patients, of which...
3.
Kameda T, Kataoka K, Kamiunten A, Hidaka M, Miyoshi H, Nakano N, et al.
Haematologica
. 2023 Feb;
108(8):2178-2191.
PMID: 36794502
The prognosis of aggressive adult T-cell leukemia/lymphoma (ATL) is poor, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment. In order to identify favorable prognostic patients after intensive...
4.
Sakamoto Y, Ishida T, Masaki A, Murase T, Ohtsuka E, Takeshita M, et al.
Hematol Oncol
. 2022 Aug;
40(5):876-884.
PMID: 36043457
Adult T-cell leukemia/lymphoma (ATL) patients have a very poor prognosis. The humanized anti-CCR4 therapeutic monoclonal antibody, mogamulizumab, is a key agent for ATL treatment. Our previous integrated molecular analysis demonstrated...
5.
Sakamoto Y, Ishida T, Masaki A, Takeshita M, Iwasaki H, Yonekura K, et al.
Cancer Sci
. 2021 Nov;
113(1):349-361.
PMID: 34738707
CD28, one of the costimulatory molecules, has a pivotal role in T-cell activation, and its expression is strictly regulated in normal T cells. Gain-of-function genetic alterations involving CD28 have been...
6.
Sakamoto Y, Ishida T, Masaki A, Murase T, Takeshita M, Muto R, et al.
Br J Haematol
. 2021 Aug;
195(4):571-584.
PMID: 34405395
Adult T-cell leukaemia/lymphoma (ATL) patients have a poor prognosis. Here, we investigated the impact of TP53 gene mutations on prognosis of ATL treated in different ways. Among 177 patients, we...
7.
Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma
Sakamoto Y, Ishida T, Masaki A, Takeshita M, Iwasaki H, Yonekura K, et al.
Br J Haematol
. 2020 Nov;
192(2):281-291.
PMID: 33205842
Multiple oncogenic events are involved in the development of adult T-cell leukaemia/lymphoma (ATL). Because CD28 plays a pivotal role in T-cell activation, we focused on alterations of the CD28 gene...
8.
Fujii K, Sakamoto Y, Masaki A, Murase T, Tashiro Y, Yonekura K, et al.
J Pathol Clin Res
. 2020 Oct;
7(1):52-60.
PMID: 33022137
Mogamulizumab targets extracellular N-terminal domain of CCR4, which is expressed in most adult T-cell leukemia/lymphoma (ATL) cases. Recently, we reported that CCR4 C-terminal gain-of-function mutations were frequent in ATL cases,...
9.
Furukawa Y, Hamada H, Kamikawaji K, Unoki T, Inoue H, Tashiro Y, et al.
J Infect Chemother
. 2019 Sep;
26(2):279-281.
PMID: 31543435
We report an AIDS patient with a high HIV RNA copy number in the plasma who was successfully treated for prolonged Mycobacterium avium bacteremia and other complications. An HIV-infected patient...
10.
Sakamoto Y, Ishida T, Masaki A, Murase T, Yonekura K, Tashiro Y, et al.
Blood
. 2018 Jun;
132(7):758-761.
PMID: 29930010
No abstract available.